Keywords
ELISA analyzer
Allergen-specific IgE
AD and PS
How to Cite
Abstract
Introduction: The fungal allergy in the progress of atopic dermatitis (AD) and psoriasis (PS) are of special interest and determines the relevance in the study. The aim of the study to conduct a comparative analysis of the sensitization spectrum to fungal allergens in patients with atopic dermatitis and psoriasis.
Materials and methods. The study involved patients with AD (Group I, n = 53) and PS (Group II, n=53) and aged group (15-60) years old. Sensitization to fungal allergens was determined by skin prick testing using standardized fungal allergens: Candida albicans, Alternaria alternata, Aspergillus fumigatus, Cladosporium herbarum, Penicillium notatum (ThermoFisher Scientific, Dubai). The concentration of allergen-specific IgE to a mixture of fungal allergens: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Alternaria alternata (ThermoFisher Scientific, Dubai) were determined by indirect immunofluorescent analysis on a ELISA analyzer. The IgE level test of positive was considered in IgE level ≥ 0.35 kU/l.
Results: The highest frequency of sensitization to fungi of the genus Cladosporium herbarum, Aspergillus fumigatus and Alternaria alternata were established In the group of patients with PS. The frequency of sensitization to fungi was higher in the group of patients with PS than in the group of patients with AD. Sensitization to a mixture of fungus allergens, according to the concentration of allergen-specific IgE, it were observed in the group of patients through compared with the group of patients in PS was : 2.7% and AD was 7.5%. Therefore, fungal allergy may play an important role in the etiopathogenesis of AD and PS.
Recommendation: The study of the diagnosis and treatment of these pathologies, including a specific allergological examination of patients with AD and PS. To study of the genotyping of fungi causing human infection.
References
Alexander H., et al (2020). The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br. J. Dermatol., vol. 182, no. 6, pp. 1331–1342. doi: 10.1111/bjd.18643.
Bacher, P., et al (2019). Human anti-fungal Th17 immunity and pathology rely on crossreactivity against Candida albicans. Cell , vol. 176, pp. 101-1 1340–1355. doi: 10.1016/cell.2019.01.041
Barilo A.A., Smirnova S.V.(2020). The role of nutritional factors and food allergies in the development of psoriasis. V. 89, No. 1. S. 60–68. doi: 10.24411/0042-8833-2020-10002.
Rebrova O.Y. (2003). Statistical analysis of medical data. Application of the STATISTICA application package. Moscow: MediaSfera, 312 p
Barilo A.A., Smirnova S.V.(2020) The comparative analysis of the spectrum of sensitization to food, pollen and fungal allergens in patients with atopic dermatitis and psoriasis. vol. 89, no. 5, pp. 28–34. doi: 10.24411/0042-8833-2020-10063.
Goncharov A.A., Dolgikh O.V.(2021). Immunological and genetic features of pathogenetic association between psoriasis and colonic dysbiosis. Journal of Infection and Immunity, vol. 11, no. 2, pp. 237–248. doi: 10.15789/2220-7619-IAG-1277.
Sinitsyn B.F. (2019). Detecting a psoriatic antigen analogous to infectious prion proteins. Journal of Infection and Immunity, vol. 9, no. 3–4, pp. 589–594. doi: 10.15789/2220-7619-2019-3-4-589-594.
Campana R et al (2017). Molecular aspects of allergens in atopic dermatitis. Curr. Open. Allergy Clin. Immunol.,vol. 17, no. 4, pp. 269–277. doi: 10.1097/ACI.000000000000378.
Hurabielle, C., et al(2020). Immunity to commensal skin fungi promotes psoriasiform skin inflammation. Proc. Natl. Acad. Sci. USA, vol. 117, no. 28, pp. 101-1 16465–16474. doi: 10.1073/pnas.2003022117.
Dey D., Mondal P., Laha A., et al (2019). Sensitization to common aeroallergen in the atopic population of West Bengal, India: an investigationby skin prick test. Int Arch Allergy Immunol. 178 [1]: 60–5.DOI: https://doi.org/10.1159/000492584.
Bieber, T (2022). Atopic Dermatitis: An Expanding Therapeutic Pipeline for a Complex Disease. Nat. Rev. Drug Discov. 21, 21–40.
Blicharz, L.; Rudnicka, L.; Samochocki, Z (2019). Staphylococcus Aureus: An Underestimated Factor in the Pathogenesis of Atopic Dermatitis? Postep. Dermatol. Alergol. 36, 11–17.
Hamm, P.S.; Mueller, R.C.; et al(2020), A. Keratinophilic Fungi: Specialized Fungal Communities in a Desert Ecosystem Identified Using Cultured-Based and Illumina Sequencing Approaches. Microbiol. Res. 239, 126530.
Berkow, E.L.; Lockhart, S.R.; Ostrosky-Zeichner, L(2020). Antifungal Susceptibility Testing: Current Approaches. Clin. Microbiol. Rev. 33, e00069-19.
Swaney, M.H.; Sandstrom, S.; Kalan, L.R.( 2022) .Cobamide Sharing Is Predicted in the Human Skin Microbiome. mSystems,7, e0067722.
Li, X.; Wang, T.; Fu, B.; Mu, X.( 2022) Improvement of Aquaculture Water Quality by Mixed Bacillus and Its Effects on Microbial Community Structure. Environ. Sci. Pollut. Res. Int. 29, 69731–69742.
Kim, H.-J.; Oh, H.N et al (2022). Aged Related Human Skin Microbiome and Mycobiome in Korean Women. Sci. Rep. 12, 2351.
Edslev, S.M.; Andersen, P.S(2021). Identification of Cutaneous Fungi and Mites in Adult Atopic Dermatitis: Analysis by Targeted 18S RRNA Amplicon Sequencing. BMC Microbiol. 21, 72.
Woo, Y.R.; Cho, et al (2022) Characterization of Distinct Microbiota Associated with Scalp Dermatitis in Patients with Atopic Dermatitis. J. Clin. Med. 11, 1735.
Bax, C.E.; Khurana, M.C.; (2021). New-Onset Head and Neck Dermatitis in Adolescent Patients after Dupilumab Therapy for Atopic Dermatitis. Pediatr. Dermatol. 38, 390–394.
Waldman RA, DeWane et al (2020): a multi-institution retrospective medical record review. J Am Acad Dermatol.82[1]:230-232.
Tokura, Y.; Hayano, S(2022). Subtypes of Atopic Dermatitis: From Phenotype to Endotype. Allergol. Int. Off. J. Jpn. Soc. Allergol.71, 14–24.
Thammahong, A.; Kiatsurayanon, C. ( 2020).The Clinical Significance of Fungi in Atopic Dermatitis. Int. J. Dermatol. 59, 926–935.
Simpson EL, Paller AS, Siegfried EC, et al(2020). Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol.156[1]:44-56.